In breast cancer, patients with mutated p53 have more than three times increased risk of recurrence and death compared to patients with wild-type p53, but co-expression of p53γ and mutated p53 leads to similar beneficial prognostic outcomes as those expressing wild-type p53 only [8]. This evidence concerns the gene TP53 and breast cancer.